|
|
||||||||
and CD8+ T Cells Restore Host Defenses Against Pneumocystis carinii in Mice Depleted of CD4+ T Cells1


,
,

*
Section of Pulmonary/Critical Care,
Gene Therapy Program, and
Section of Hematology/Oncology, Louisiana State University Medical Center School of Medicine, New Orleans, LA 70112
| Abstract |
|---|
|
|
|---|
by gene transfer into the lung tissue results in
clearance of PC from the lungs in the absence of CD4+
lymphocytes. This resolution of infection was associated with a
>4-fold increase in recruited CD8+ T lymphocytes and NK
cells into the lungs. The role of CD8+ T cells as effector
cells in this model was further confirmed by a lack of an effect of
IFN-
gene transfer in scid mice or mice depleted of
both CD4+ and CD8+ T cells. Cytokine mRNA
analysis revealed that recruited, lung-derived CD8+ T cells
had greater expression of IFN-
message in animals treated with the
IFN-
gene. These results indicate that CD8+ T cells are
capable of clearing PC pneumonia in the absence of CD4+ T
cells and that this host defense function of CD8+ T cells,
as well as their cytokine repertoire, can be up-regulated through
cytokine gene transfer. | Introduction |
|---|
|
|
|---|
is likely to play a key role in host defense against
PC infection. Lymphocytes exposed to PC organisms 5 or the major
surface glycoprotein of PC 6 in vitro elaborate IFN-
and
lymphocytes recovered from HIV-infected individuals are deficient in
IFN-
production 7 . Studies in IFN-
receptor knockout mice
demonstrate that these mice are not permissive to passive acquisition
of PC 8 . Moreover, studies in IFN-
knockout mice 9 , or in
scid mice reconstituted with splenocytes from IFN-
knockout mice 10 , demonstrate that IFN-
is not essential for
clearance of PC. However, previous studies from our group have
demonstrated that aerosolized, rIFN-
can ameliorate PC infection in
mice depleted of CD4+ T lymphocytes 11 . Based on these
data, we postulated that in mice depleted of CD4+ T cells
using a mAb, overexpression of IFN-
in the lung might substitute for
CD4+ T lymphocytes and mediate clearance of PC pneumonia. | Materials and Methods |
|---|
|
|
|---|
To selectively overexpress IFN-
in the lung, we constructed
an E1-deleted, replication-deficient adenovirus encoding the murine
IFN-
cDNA (AdIFN) driven by the CMV immediate early promoter 12 .
The murine IFN-
cDNA (obtained from Dr. Opdenakker, Rega Institute
of Catholieke University, Leuven, Belgium) was subcloned into
pACCMV.PLA (obtained from Robert Gerard, University of Texas
Southwestern Medical Center, Dallas, TX). AdIFN was generated by
cotransfecting with pJM17 (obtained from Frank L. Graham, McMaster
University, Hamilton, Ontario, Canada) into 293 cells. Isolated plaques
were propagated in 293 cells, and viral DNA was screened by Southern
blot analysis. Production of secreted IFN-
by individual clones and
in bronchoalveolar lavage fluid (BALF) was measured by ELISA (Genzyme,
Cambridge, MA) with a sensitivity of 5 pg/ml 13 . AdLuc (provided by
Robert Gerard), which encodes the firefly luciferase gene in the E1
region, was used as a control vector. Both viruses were propagated in
293 cells, purified by ultracentrifugation over a CsCl gradient, and
titered by a plaque assay on 293 cells as described previously 14 .
Viral stocks contained <1 replication-competent adenovirus per
107 plaque-forming units (PFU) (as determined by a
lack of cytopathic effect on A549 cells, at a multiplicity of infection
of 10). The particle:PFU ratio was <100:1, and virus stocks contained
<0.01 ng/ml of endotoxin as determined by the QCL-1000
Limulus lysate assay (BioWhittaker, Walkersville,
MD).
PC Inoculation
The PC inoculum was prepared as previously described 15 . Briefly, athymic mice with PC pneumonia were injected with a lethal dose of pentobarbital, and the lungs were aseptically removed and frozen for 30 min in 1 ml of PBS at -70°C. Frozen lungs were homogenized in 10 ml of PBS (Model 80 Stomacher; Tekmar Instruments, Cincinnati, OH), filtered through sterile gauze, and pelleted at 500 x g for 10 min at 4°C. The pellet was resuspended in PBS, and a 1:4 dilution was stained with modified Giemsa stain (Diff-Quik; Baxter, McGaw Park, IL). The number of PC cysts was quantified microscopically 15 , and the inoculum concentration was adjusted to 2 x 106 cysts/ml. Gram stains were performed on the inoculum to exclude contamination with bacteria.
Monoclonal Abs
Anti-CD4 Ab was prepared as previously described 15 . Briefly, the hybridoma GK1.5, which produces a rat IgG2b Mab against murine CD4 16 , was obtained from the American Type Culture Collection (Manassas, VA). Harvesting of the Ab as ascites from pristane-primed, uninfected athymic mice took place in the Monoclonal Ab Core Laboratory facility at Louisiana State University Medical Center (LSUMC). The Ab was precipitated with an equal volume of saturated ammonium sulfate and dialyzed against PBS overnight, and the IgG content was quantitated by cellulose acetate electrophoresis and densitometry. The Ab was stored at -70°C until use. All lots of Ab contained <0.01 ng/ml of endotoxin as determined by the QCL-1000 Limulus lysate assay. Heat denaturation of the Ab ablates its CD4-depleting capacity as well as its ability to modify lung host defenses 17 . YTS169.4, a depleting rat anti-CD8 mAb, was provided by Dr. Jim Beck (University of Michigan, Ann Arbor, MI) 18 .
Adenoviral gene transfer in PC inoculation
Recipient male, 7- to 8-wk-old BALB/c or scid mice were purchased from Hilltop Laboratories (Gilroy, CA) and housed in pathogen-free conditions in the LSUMC vivarium. BALB/c mice were treated with 0.3 mg of rat IgG or a depleting anti-CD4 Ab (GK1.5, ATCC no. TIB 207) i.p. and then randomized to receive 109 PFU of AdIFN or AdLuc intratracheally 3 days later. Three days after adenovirus administration, animals were challenged with 2 x 105 PC cysts intratracheally. Mice continued to receive rat IgG or GK1.5 weekly until sacrifice. We have previously shown that in BALB/c mice, weekly GK1.5 maintains a continued state of >97% CD4-depletion in blood and lymphoid tissue for up to 14 wk 15 . Mice were sacrificed at serial intervals up to 6 wk. Scid mice received identical gene transfer and PC inoculation and were sacrificed at 6 wk. For double depletion experiments, 7- to 8-wk-old BALB/c mice received 0.3 mg of GK1.5 and 0.5 mg of YTS169.4 or an equivalent amount of rat IgG i.p. 3 days before adenoviral-mediated gene transfer. Three days after adenovirus administration, animals were challenged with 2 x 105PC cysts intratracheally. Mice continued to receive rat IgG or GK1.5/YTS 169.4 weekly until sacrifice at 6 wk. Our laboratory has previously demonstrated that coadministration of these Abs results in >95% depletion in both CD4+ and CD8+ T lymphocytes for at least 6 wk 18 .
Histology
After a lethal dose of pentobarbital, mice were exsanguinated by aortic transection. The trachea was exposed through a midline incision and cannulated with a polyethylene catheter. The lungs were fixed by administration of 10% neutral formalin to 20 cm H20. Paraffin-embedded sections were stained with hematoxylin and eosin or Gomori-methenamine silver (GMS) and scored blindly for alveolar and perivascular inflammation and PC infection score, respectively, as previously described 19, 20, 21 . Briefly, tissue blocks were sectioned at 5-µM thickness and stained with GMS. The extent of infection with PC was scored using a semiquantitative scale ranging from 0 (no visible infection) to 4 (cysts throughout most alveolar regions). This method has been shown to correlate in a double-blind fashion with organism counts from homogenized lung tissue 18 .
FACS analysis
At the time of sacrifice, cells from BALF were recovered by centrifugation at 500 x g, washed with sterile PBS, and resuspended at 106 cells/ml. Cells (50,000) were used for cytospins and stained with Diff-Quik. BALF cells were seeded at a density of 450,000 cells per well in a Limbro/TiterTek microtiter plate (Flow Laboratories, McLean, VA). Cells were incubated with PBS or stained with FITC anti-mouse CD3e (145-2C11), phycoerythrin (PE) anti-mouse CD4 (RM4-4), PE-anti rat CD8a (53-6.7), or respective isotype controls (all Abs from PharMingen, San Diego, CA). NK cells were detected by staining with Dx-5 (PharMingen, San Diego, CA). A minimum of 5,000 double-labeled cells were analyzed on an EPICS elite cell sorter (Coulter, Hialeah, FL). Nonlymphocyte cells were omitted from analysis by forward-angle scatter.
Cytokine mRNA analysis in CD8+ T cells by cDNA-equalized RT-PCR
CD8+ T cells were purified from both BALF and hilar lymph nodes at both 14 and 28 days after PC inoculation using murine-specific CD8 Dynabeads (Dynal, Lake Success, NY). Briefly, lavaged cells or cells derived from hilar lymph nodes were pooled from three animals in each group, washed, counted, and then incubated with the correct number of Dynabeads, following the manufacturers protocol. Cells and beads were mixed at 4°C for 20 min. Tubes were placed in a Dynal magnetic particle concentrator magnet for 2 min, and the supernatant was removed by pipetting. Remaining cells and beads were washed twice more with RPMI 1640 and recovered by centrifugation. Beads were detached by resuspending the beads in detachment buffer (2 parts human serum + 2 parts 2% EDTA + 1 part RPMI 1640) and gently shaking for 20 min at room temperature. Detached cells were recovered after placing the tube in the magnet for 1 min. The purity of the CD8+ T cell preparation was >98% from both BALF and node specimens as measured by flow cytometry.
Transcripts for IFN-
, IL-2, IL-4, IL-5, and ß-actin were measured
in these cell preparations by semiquantitative RT-PCR analysis as
previously described 22, 23 . Briefly, RNA was isolated by lysing
106 cells in Tri-zol (Life Technologies/BRL, Gaithersburg,
MD) following the manufacturers protocol. Reverse transcription was
conducted in 40-µl reactions with a final concentration of 500 pM
random hexamer as primer, 1 mM dATP-dGTP-dTTP, and 0.03 mM dCTP (all
from Pharmacia), 1x PCR buffer (50 mM KCl, 25 mM MgCl2,
and 10 mM Tris (pH 8.3)), 40 U RNasin (Promega, Madison, WI), 1 mM DTT,
and 400 units Moloney murine leukemia virus-reverse transcriptase. cDNA
synthesis was quantified by electrophoresing a 3-uL aliquot on a 6%
polyacrylamide gel and exposing the gel on a PhosphorImager screen
(Molecular Dynamics, Mountain View, CA). Synthesized cDNA mass was
calculated using ImageQuant software (Molecular Dynamics) as previously
described 22 and further assessed by the ability to amplify ß-actin
by PCR using actin-specific primers. After this analysis, equivalent
masses of cDNA were analyzed by PCR using gene specific primers
(IFN-
-A, 5'-AGCGGCTGACTGAACTCAGATTGTAG-3'; IFN-
-B,
5'-GTCACAGTTTTCAGCTGTATAGGG-3'; IL-2-A,
5'-TGATGGACCTACAGGAGCTCCTGAG-3'; IL-2-B,
5'-GAGTCAAATCCAGAACATGCCGCAG-3'; IL-4-A,
5'-CGAAGAACACCACAGAGAGTGAGCT-3'; IL-4-B,
5'-GACTCATTCATGGTGCAGCTTATCG-3'; IL-5-A,
5'-ATGACTGTGCCTCTGTGCCTGGAGC-3'; IL-5-B,
5'-CTGTTTTTCCTGGAGTAAACTGGGG-3'; ß-actin-A,
5'-TGGAATCCTGTGGCATCCATGAAAC-3'; ß-actin-B,
5'-TAAAACGCAGCTCAGTAACAGTCCG-3'). ß-actin was coamplified in a
parallel reaction to control for PCR efficiency and cDNA integrity.
After PCR, a 10-µl aliquot of the reaction was electrophoresed on a
6% denaturing polyacrylamide gel. The gel was dried, exposed, and
analyzed on a PhosphorImager. Bands representing the cytokine genes of
interest were quantitated and normalized to ß-actin expression.
Statistical analysis
Data were analyzed using StatView Software (Carlsbad, CA). Differences between means were analyzed by analysis of variance with Fishers follow-up testing.
| Results |
|---|
|
|
|---|
To selectively overexpress IFN-
in the lung, we constructed an
E1-deleted, replication-deficient adenovirus encoding the murine
IFN-
cDNA (AdIFN) driven by the CMV-immediate early promoter 12 .
When given intratracheally, this vector resulted in dose-dependent
levels of IFN-
in the BALF of rats 12 and mice. Pilot experiments
revealed that intratracheal inoculation of 109 or
108 PFU of AdIFN into 6- to 8-wk-old BALB/c mice
(n = 4/dose) resulted in peak levels of 1400 ±
436 or 256 ± 39 pg/ml of IFN-
in BALF 3 days after gene
transfer. No IFN-
was detected in the BALF of mice receiving vehicle
or equal doses of AdLuc (data not shown). However, the 109
PFU dose resulted in the strongest induction of class II MHC (Ia)
expression on alveolar macrophages, and thus, this dose was used for
all subsequent experiments. BALB/c mice were randomized to receive
109 PFU of AdIFN or AdLuc followed by PC inoculation 3 days
after gene transfer. Expression of IFN-
was determined by ELISA in
the BALF in both CD4+ and CD4- mice on days 4,
7, 14, and 28 after vector administration. AdIFN-transduced animals had
almost two orders of magnitude greater IFN-
levels in the BALF at
day 4, 7, and 14 (Fig. 1
). As we have
previously observed 23 , the expression of IFN-
was prolonged in
CD4-depleted mice, presumably due to a reduced anti-adenoviral
immune response in this group of animals 23, 24 . Small amounts of
IFN-
were detected in both CD4+ and CD4-depleted
(CD4-) animals transduced with AdLuc (Fig. 1
). In
CD4+ animals that clear the infection over this time,
IFN-
levels became undetectable by day 28. However, IFN-
remained
elevated in AdLuc-transduced CD4-depleted animals coincident with
ongoing PC infection.
|
To determine whether IFN-
overexpression enhanced resolution of
PC infection, mice were pretreated with 109 PFU of AdIFN,
AdLuc, or an equal volume of PBS intratracheally. Three days later, all
mice were challenged with 2 x 105 PC cysts. Control
CD4-depleted mice developed progressive, severe infection after
inoculation of PC (Fig. 2
, PBS data not
shown). In contrast, CD4-depleted mice that received the AdIFN vector
followed by inoculation with PC showed moderate levels of PC infection
during the first 2 wk, but then subsequently cleared the infection
within 46 wk (Fig. 2
). Both PBS- and AdLuc-treated animals showed
similar levels of infection throughout the study (data not shown).
|
Clearance of infection observed in CD4-depleted, AdIFN-treated
mice was associated with significant recruitment into lung of
CD3+ T cells, which were principally of the
CD8+ phenotype in the BALF. (Fig. 3
A). Moreover, AdIFN treatment
resulted in significant increases in recruited NK cells in BALF of
CD4-depleted animals (Fig. 3
B). Approximately 45% of these
NK cells were CD3+, which explains, in part, the
discrepancy between the total CD3+ and CD8+
population (Fig. 3
A). Increases in T cells and NK cells in
the BALF paralleled peribronchiolar and perivascular accumulations of
lymphocytes as determined by blindly scored hematoxylin and
eosin-stained lung sections, as previously described (Refs. 15, 20, 25,
and data not shown).
|
To determine whether recruited CD8+ T cells associated
with AdIFN were effector cells in AdIFN-induced clearance of PC, we
investigated AdIFN in 6- to 8-wk-old, male scid mice, which
lack both CD4+ and CD8+ T cells, or mice
depleted of both CD4+ and CD8+ T cells (using
mAbs). Mice were pretreated with 109 PFU of AdIFN, AdLuc,
or PBS 3 days before PC challenge. Mice were analyzed for intensity of
PC infection at 6 wk. In both scid and double-depleted mice,
AdIFN did not enhance the clearance of PC pneumonia (Fig. 4
, A and B),
despite persistent expression of IFN-
in the BALF at the 6-wk
sacrifice point (data not shown).
|
To investigate whether AdIFN was influencing the lung/cytokine
microenvironment, CD8+ T cells were purified from BALF and
hilar lymph nodes at 14 and 28 days after PC inoculation and analyzed
for cytokine mRNA expression. We focused our analysis on the Tc1
cytokines IL-2 and IFN-
, and the Tc2 cytokines IL-4 and IL-5. Using
cDNA-equalized PCR, we observed a significant increase in IFN-
mRNA
in purified CD8+ T cells in AdIFN-treated, CD4-depleted
mice at both 14 and 28 days after PC infection (Fig. 5
). No IL-2, IL-4, or IL-5 mRNA
expression was detected in AdIFN-treated or control groups at either of
these two time points.
|
| Discussion |
|---|
|
|
|---|
Our results described in this paper suggest that CD8+ T
cells can be driven by the tissue cytokine milieu to migrate into
infected lung tissue and become effector cells in PC pneumonia. We
observed significantly higher levels of IFN-
mRNA in
CD8+ T cells from AdIFN-treated mice at both 2 and 4 wk
after challenge with PC. This is not likely due to adenoviral
transduction of these cells, as these cells are not present in the
lungs of mice at the time of administration of the adenovirus.
Moreover, PCR analysis for CMV promoter sequences in these cells was
negative (data not shown). The effector systems utilized by
CD8+ T cells in our model remain unclear. Putative effector
mechanisms of CD8+ T cells include cytokine elaboration
such as TNF-
, TNF-ß, or IFN-
29, 30 and cytotoxic effector
molecules, such as perforin or granzyme 30 . CD8+ T cells
have recently been shown to have cytokine patterns analogous to Th1 and
Th2 CD4+ T cells, termed Tc1 and Tc2 29, 30 . It has also
been demonstrated that naïve CD8+ T cells can be
induced into a Tc1 phenotype by IFN-
29 . Thus, we postulate that
overexpression of IFN-
in both normal and CD4-depleted mice causes
naïve CD8+ T cells in lung tissue to adopt a
Tc1-like cytokine profile, expressing IL-2 and IFN-
, and that these
cells are effector cells in vivo against PC infection. Although we did
not detect IL-2 mRNA in analysis of CD8+ T cells at 2 and 4
wk after PC inoculation, IL-2 may only be expressed early at the time
of initial Ag presentation 31, 32 . Thus, we are in the process of
phenotyping cytokine profiles in CD8+ T cells at earlier
time points in this model.
Possible cytotoxic mechanisms include elaboration of perforin or
granzyme 33, 34 or an effect of CD8+ cells on other
effector cells, such as macrophages, which have been recently shown to
be required for host defense against PC 35 . IFN-
increases TNF
production by rat alveolar macrophages exposed to PC in vitro 36 .
Moreover, we have previously shown that in vivo neutralization of both
TNF and lymphotoxin abrogates host defense against PC in normal mice as
well as CD4-depleted mice 25 . Thus, these two mediators could be
involved in the beneficial results we observed in this model. However,
we saw no difference in peak TNF levels in lung lavage fluid between
AdIFN and control animals 3 h after PC challenge, which is the
time of peak alveolar macrophage release of TNF in this model (Ref. 37,
and data not shown). Recently, the roles of granzyme B and perforin
have been investigated in another pulmonary pathogen in a mouse model
of tuberculosis 38 . Although CD8+ T cells are critical to
contain growth of Mycobacterium tuberculosis in the mouse
lung 39 , growth was not affected in mice deficient in perforin or
granzyme B 38 . An important difference, however, is that host defense
in M. tuberculosis relies on granuloma formation 40, 41 ,
which is not observed in PC pneumonia. While CD8+ T cells
are required, the clearance of PC by IFN-
may be through a combined
CD8+/NK cell mechanism. Reconstituted scid mice
with homozygous disruption of the IFN-
gene ultimately clear an
acute challenge with PC 10 . Moreover, mice lacking the IFN-
receptor are not permissive to passive acquisition of PC 8 . Thus,
IFN-
itself does not appear to be critical for organism
clearance in reconstituted scid or CD4-replete mice. In a
recent study by Rudmann et al. 9 , mice lacking both TNF receptor
genes (TNFRI and TNFRII), as well as the IFN-
gene,
developed severe PC infection despite the presence of CD4+
T lymphocytes. Taken together, these data suggest that IFN-
is not
essential for host defenses against PC but is part of a cytokine
response, which is critical for optimal host defenses. Moreover, our
data suggest that IFN-
can be used pharmacologically to increase
host defenses and experimental animals lacking CD4+ T
lymphocytes. Our data are also in agreement with a prior study that
demonstrated efficacy of rIFN-
in an aerosol form, delivered to mice
with established PC infection 11 . However, the mechanism through
which IFN-
works when delivered as an aerosol has not been
demonstrated. In this study, lung inflammation was reduced in the
IFN-
-treated group 11 , however, it remains unclear if this was
secondary to a decrease in organism burden at the end of the course of
IFN-
.
In conclusion, the combination of IFN-
and CD8+ T cells
can effectively eradicate PC pneumonia even in the absence of host
CD4+ T cells. These data not only have implications for
novel treatment strategies for PC pneumonia but also may apply to other
opportunistic infections in HIV-infected hosts.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Jay K. Kolls, Louisiana State University School of Medicine, Room 3205, 1901 Perdido Street, New Orleans, LA 70112. E-mail address: ![]()
3 Abbreviations used in this paper: PC, Pneumocystis carinii; PFU, plaque-forming unit; BALF, bronchoalveolar lavage fluid. ![]()
Received for publication September 1, 1998. Accepted for publication November 25, 1998.
| References |
|---|
|
|
|---|
interferon in the host immune and inflammatory responses to Pneumocystis carinii infection. Infect. Immun. 65:373.[Abstract]
. Infect. Immun. 59:3859.
gene. Am. J. Physiol. 272:L852.
by alveolar macrophages: modulation by pentamidine isethionate. Immunol. Lett. 34:303.
This article has been cited by other articles:
![]() |
M. P. Nelson, A. E. Metz, S. Li, C. A. Lowell, and C. Steele The Absence of Hck, Fgr, and Lyn Tyrosine Kinases Augments Lung Innate Immune Responses to Pneumocystis murina Infect. Immun., May 1, 2009; 77(5): 1790 - 1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Salat, J. Jelinek, J. Chmelar, and J. Kopecky Efficacy of Gamma Interferon and Specific Antibody for Treatment of Microsporidiosis Caused by Encephalitozoon cuniculi in SCID Mice Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2169 - 2174. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ruan, L. McKinley, M. Zheng, X. Rudner, A. D'Souza, J. K. Kolls, and J. E. Shellito Interleukin-12 and Host Defense against Murine Pneumocystis Pneumonia Infect. Immun., May 1, 2008; 76(5): 2130 - 2137. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Empey, M. Hollifield, and B. A. Garvy Exogenous Heat-Killed Escherichia coli Improves Alveolar Macrophage Activity and Reduces Pneumocystis carinii Lung Burden in Infant Mice Infect. Immun., July 1, 2007; 75(7): 3382 - 3393. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Millward, M. Caruso, I. L. Campbell, J. Gauldie, and T. Owens IFN-{gamma}-Induced Chemokines Synergize with Pertussis Toxin to Promote T Cell Entry to the Central Nervous System J. Immunol., June 15, 2007; 178(12): 8175 - 8182. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Lasbury, S. Merali, P. J. Durant, D. Tschang, C. A. Ray, and C.-H. Lee Polyamine-mediated Apoptosis of Alveolar Macrophages during Pneumocystis Pneumonia J. Biol. Chem., April 13, 2007; 282(15): 11009 - 11020. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Rapaka, E. S. Goetzman, M. Zheng, J. Vockley, L. McKinley, J. K. Kolls, and C. Steele Enhanced Defense against Pneumocystis carinii Mediated by a Novel Dectin-1 Receptor Fc Fusion Protein J. Immunol., March 15, 2007; 178(6): 3702 - 3712. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Bhagwat, F. Gigliotti, H. Xu, and T. W. Wright Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease Am J Physiol Lung Cell Mol Physiol, December 1, 2006; 291(6): L1256 - L1266. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Gigliotti, E. L. Crow, S. P. Bhagwat, and T. W. Wright Sensitized CD8+ T Cells Fail To Control Organism Burden but Accelerate the Onset of Lung Injury during Pneumocystis carinii Pneumonia Infect. Immun., November 1, 2006; 74(11): 6310 - 6316. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. McKinley, A. J. Logar, F. McAllister, M. Zheng, C. Steele, and J. K. Kolls Regulatory T Cells Dampen Pulmonary Inflammation and Lung Injury in an Animal Model of Pneumocystis Pneumonia J. Immunol., November 1, 2006; 177(9): 6215 - 6226. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Freeman, J. Davis, V. L. Anderson, W. Barson, D. N. Darnell, J. M. Puck, and S. M. Holland Pneumocystis jiroveci Infection in Patients With Hyper-Immunoglobulin E Syndrome Pediatrics, October 1, 2006; 118(4): e1271 - e1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. McAllister, S. Ruan, C. Steele, M. Zheng, L. McKinley, L. Ulrich, L. Marrero, J. E. Shellito, and J. K. Kolls CXCR3 and IFN Protein-10 in Pneumocystis Pneumonia J. Immunol., August 1, 2006; 177(3): 1846 - 1854. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Lasbury, P. J. Durant, C. A. Ray, D. Tschang, R. Schwendener, and C.-H. Lee Suppression of Alveolar Macrophage Apoptosis Prolongs Survival of Rats and Mice with Pneumocystis Pneumonia. J. Immunol., June 1, 2006; 176(11): 6443 - 6453. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. McAllister, C. Steele, M. Zheng, J. E. Shellito, and J. K. Kolls In Vitro Effector Activity of Pneumocystis murina-Specific T-Cytotoxic-1 CD8+ T Cells: Role of Granulocyte-Macrophage Colony-Stimulating Factor Infect. Immun., November 1, 2005; 73(11): 7450 - 7457. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, S. D. Tachado, N. Patel, J. Zhu, A. Imrich, P. Manfruelli, M. Cushion, T. B. Kinane, and H. Koziel Negative regulatory role of mannose receptors on human alveolar macrophage proinflammatory cytokine release in vitro J. Leukoc. Biol., September 1, 2005; 78(3): 665 - 674. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. N. Meissner, S. Swain, M. Tighe, A. Harmsen, and A. Harmsen Role of Type I IFNs in Pulmonary Complications of Pneumocystis murina Infection J. Immunol., May 1, 2005; 174(9): 5462 - 5471. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Wright, G. S. Pryhuber, P. R. Chess, Z. Wang, R. H. Notter, and F. Gigliotti TNF Receptor Signaling Contributes to Chemokine Secretion, Inflammation, and Respiratory Deficits during Pneumocystis Pneumonia J. Immunol., February 15, 2004; 172(4): 2511 - 2521. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Thullen, A. D. Ashbaugh, K. R. Daly, M. J. Linke, P. E. Steele, and P. D. Walzer Sensitized Splenocytes Result in Deleterious Cytokine Cascade and Hyperinflammatory Response in Rats with Pneumocystis Pneumonia despite the Presence of Corticosteroids Infect. Immun., February 1, 2004; 72(2): 757 - 765. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Mc Allister, C. Steele, M. Zheng, E. Young, J. E. Shellito, L. Marrero, and J. K. Kolls T Cytotoxic-1 CD8+ T Cells Are Effector Cells against Pneumocystis in Mice J. Immunol., January 15, 2004; 172(2): 1132 - 1138. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Steele, L. Marrero, S. Swain, A. G. Harmsen, M. Zheng, G. D. Brown, S. Gordon, J. E. Shellito, and J. K. Kolls Alveolar Macrophage-mediated Killing of Pneumocystis carinii f. sp. muris Involves Molecular Recognition by the Dectin-1 {beta}-Glucan Receptor J. Exp. Med., December 1, 2003; 198(11): 1677 - 1688. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Swain, S. J. Lee, M. C. Nussenzweig, and A. G. Harmsen Absence of the Macrophage Mannose Receptor in Mice Does Not Increase Susceptibility to Pneumocystis carinii Infection In Vivo Infect. Immun., November 1, 2003; 71(11): 6213 - 6221. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ruan, C. Tate, J. J. Lee, T. Ritter, J. K. Kolls, and J. E. Shellito Local Delivery of the Viral Interleukin-10 Gene Suppresses Tissue Inflammation in Murine Pneumocystis carinii Infection Infect. Immun., November 1, 2002; 70(11): 6107 - 6113. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Gilmartin and H. Koziel Pneumocystis Carinii Pneumonia in Adult Non-HIV Disorders J Intensive Care Med, November 1, 2002; 17(6): 283 - 301. [Abstract] [PDF] |
||||
![]() |
C. Steele, M. Zheng, E. Young, L. Marrero, J. E. Shellito, and J. K. Kolls Increased Host Resistance against Pneumocystis carinii Pneumonia in {gamma}{delta} T-Cell-Deficient Mice: Protective Role of Gamma Interferon and CD8+ T Cells Infect. Immun., September 1, 2002; 70(9): 5208 - 5215. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Casciotti, K. H. Ely, M. E. Williams, and I. A. Khan CD8+-T-Cell Immunity against Toxoplasma gondii Can Be Induced but Not Maintained in Mice Lacking Conventional CD4+ T Cells Infect. Immun., February 1, 2002; 70(2): 434 - 443. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. BECK, M. J. ROSEN, and H. H. PEAVY Pulmonary Complications of HIV Infection . Report of the Fourth NHLBI Workshop Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2120 - 2126. [Full Text] [PDF] |
||||
![]() |
A. J. Simpson, W. A. H. Wallace, M. E. Marsden, J. R. W. Govan, D. J. Porteous, C. Haslett, and J.-M. Sallenave Adenoviral Augmentation of Elafin Protects the Lung Against Acute Injury Mediated by Activated Neutrophils and Bacterial Infection J. Immunol., August 1, 2001; 167(3): 1778 - 1786. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xing, A. Zganiacz, J. Wang, and S. K. Sharma Enhanced Protection Against Fatal Mycobacterial Infection in SCID Beige Mice by Reshaping Innate Immunity with IFN-{{gamma}} Transgene J. Immunol., July 1, 2001; 167(1): 375 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Mansharamani, D. Balachandran, I. Vernovsky, R. Garland, and H. Koziel Peripheral Blood CD4 + T-Lymphocyte Counts During Pneumocystis carinii Pneumonia in Immunocompromised Patients Without HIV Infection Chest, September 1, 2000; 118(3): 712 - 720. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |